Compare · ILMN vs RDNT
ILMN vs RDNT
Side-by-side comparison of Illumina Inc. (ILMN) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 5.6x RDNT ($6.05B).
- Over the past year, ILMN is up 127.9% and RDNT is up 9.0% - ILMN leads by 119.0 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 4 for RDNT).
- ILMN has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Illumina Inc.
- RadNet Inc.
- Price
- $225.01+0.76%
- $76.90+3.03%
- Market cap
- $33.97B
- $6.05B
- 1M return
- +18.79%
- +24.98%
- 1Y return
- +127.94%
- +8.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 10
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)
Latest RDNT
- RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by RadNet Inc.
- RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
- DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
- RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
- DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
- Director Swartz David L sold $145,449 worth of shares (2,699 units at $53.89), decreasing direct ownership by 2% to 177,013 units (SEC Form 4)
- Pres & CEO, Digital Health Wesdorp Cornelis sold $276,022 worth of shares (4,750 units at $58.11), decreasing direct ownership by 6% to 69,075 units (SEC Form 4)
- President, CEO Berger Howard G gifted 90 shares (SEC Form 4)